Orders from 1390 SEK Free delivery from 2895 SEK Ready for pickup dead drop: collect in 5 min Free parcel delivery from 2895 SEK

Substances · Cathinone derivatives

NEP

C13H19NO CAS 779974-89-9 Analytical reference material — not for human consumption
NEP, educational illustration of the molecular structure
Educational illustration of the molecular structure. This is not a photograph of the product.
Preferred name
NEP
IUPAC name
2-(ethylamino)-1-phenylpentan-1-one
Parent CAS number (reference)
779974-89-9
Molecular formula
C13H19NO
Molecular weight
205.3 g/mol
InChIKey
QQAHEGDXEXIQPR-UHFFFAOYSA-N
PubChem
CID 205593
Source
PubChem
Verified synonyms & catalog abbreviations
N-ethyl-Pentedrone N-Ethylpentedrone N-Ethylnorpentedrone

Verified Neurochemical & Toxicological Intelligence

NEP (N-Ethylpentedrone / N-Ethylnorpentedrone)

Stimulant (Selective NDRI — Norepinephrine-Dopamine Reuptake Inhibitor) Substituted cathinone (N-ethyl valerophenone)
Verified PubChem & CAS Identity C13H19NO · CAS 779974-89-9 · CID 205593
Calibrated Physical Form Pure Crystalline / Analytical Powder (≥98%)
≥98% Analytical Purity Verified 205.30 g/mol
Peer-Reviewed & Agency Citations 4 · verified sources

Receptor Telemetry & Mechanism of Action

DAT Dopaminergic Signaling Primary
NET Noradrenergic Signaling Active
SERT Serotonergic Signaling Variable

Pure monoamine transporter uptake blocker (NDRI) without substrate-induced release. In HEK293 human transporter assays (Eshleman et al., 2019), NEP potently inhibits hNET (IC50 = 101 ± 24 nM, Ki = 700 ± 180 nM) and hDAT (IC50 = 165 ± 43 nM, Ki = 182 ± 22 nM), while serotonin reuptake inhibition is ~64-fold weaker (hSERT IC50 = 10,500 ± 2,000 nM, Ki = 8,400 ± 2,100 nM). Human observational data confirm brisk heart-rate (+22.3 bpm) and systolic BP (+20.6 mmHg) increases alongside alertness, openness, and sociability.

Biotransformation & Active Metabolites

Monitored and risk-assessed by EUDA (2025–2026); specific human plasma pharmacokinetic parameters (Cmax, elimination half-life) have not yet been published in controlled trials.

Temporal Pharmacokinetics

Smooth, confident, NDRI-type stimulation offering brisk wakefulness, talkativeness, social openness, and mild tactile pleasure with less initial peripheral harshness than Hexen.

  1. Onset 10–25 minutes oral (1–8 minutes mucosal)
  2. Peak Window 1–2 hours oral (30–60 minutes mucosal)
  3. Total Window 4–6 hours oral (1–3 hours mucosal; cardiovascular elevation lasts ~4 hours)
  4. Residual / Half-Life 1–4 hours after a single dose, extending up to 12–24 hours of insomnia after repeated exposure; human plasma half-life is unverified.

Roughly 3–4 times more potent by weight than MMC/CMC cathinones: active from 10 mg, with strong stimulation at 40–60 mg. Critically, mood elevation declines rapidly within 2–3 doses while residual noradrenergic wakefulness and tachycardia stack for up to 12–24 hours—making automatic repeated exposure binges prone to severe anxiety, insomnia, and stimulant psychosis.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
10 mg (oral and mucosal)
Cognitive & Sensory

Subtle alertness, mild mood elevation, and reduced mental fatigue.

Somatic & Autonomic

Noticeable mild uptick in heart rate even at low amounts.

Light
10–25 mg (mucosal: 10–20 mg)
Cognitive & Sensory

Clean wakefulness, talkativeness, sociable confidence, and modest motivation.

Somatic & Autonomic

Moderate heart-rate increase, appetite suppression, and minimal dry mouth.

Common Reference
25–40 mg (mucosal: 20–40 mg)
Cognitive & Sensory

Clear dopaminergic mood elevation, social openness, ego boost, and heightened conversational drive.

Somatic & Autonomic

Sustained ~22 bpm heart-rate and ~21 mmHg systolic BP elevation, sweating, dry mouth, and mild vasoconstriction.

Strong
40–60 mg (oral and mucosal)
Cognitive & Sensory

Scattered hyper-stimulation, compulsive urge to redose, thought acceleration, and rising anxiety on offset.

Somatic & Autonomic

Strong tachycardia, palpitations, bruxism, muscle tension, difficulty urinating, and temporary erectile dysfunction.

Heavy / Toxic Zone
60+ mg (or multiday repeated exposure)
Cognitive & Sensory

Severe paranoia, panic, delusions, delirious thought disorganization, and rapid-onset stimulant psychosis.

Somatic & Autonomic

Dangerous hypertension, arrhythmias, chest pain, severe vasoconstriction, hyperthermia, and seizure risk.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

MAOIs (phenelzine, tranylcypromine, moclobemide, harmala alkaloids)

Potent NET/DAT reuptake blockade combined with MAO inhibition precipitates severe hypertensive crisis, hyperthermia, and cardiac arrhythmia.

Cocaine, Pyrovalerones (alpha-PVP, alpha-PHP, alpha-PiHP, MDPHP), Hexen, and 25x-NBOMe

NEP already raises heart rate disproportionately; stacking NDRIs or NBOMes risks acute vasospasm, malignant hypertension, seizures, and heart failure.

Tramadol

Synergistically lowers seizure threshold alongside adrenergic overload.

Elevated Hazard — Avoid

Serotonergic entactogens and Amphetamines (MDMA, 4-MMC, 3-MMC, 4-FMA)

NDRI blockade can interfere with substrate-releaser transport while severely compounding tachycardia, overheating, and neurocardiac strain.

Alcohol and GHB/GBL

Masks depressant intoxication during NEP's peak, risking sudden blackout and cardiac/electrolyte stress.

Caution / Receptor Attenuation

Cannabis and Psychedelics

Frequently triggers rapid heart rate, thought loops, and acute paranoia, especially during NEP's offset.

Caffeine

Heightens palpitations, restlessness, and peripheral vasoconstriction.

Structural Isomer & Sibling Comparison

Compared to its 6-carbon homologue Hexen (NEH), NEP is ~3.5-fold gentler at DAT (hDAT IC50 165 nM vs. 46.7 nM), giving NEP a smoother, less jittery, and slightly more sociable plateau than Hexen. Compared to 3-MMC/4-MMC, NEP is 3–4x more potent by weight (common 25–40 mg vs. 100–200 mg) and acts as a pure reuptake blocker rather than a serotonin releaser. Compared to alpha-PVP/alpha-PiHP, NEP is ~10x less potent at DAT and far more forgiving at 15–30 mg.

Physicochemical Stability & Storage

Physical Form: White to off-white crystalline solid, fine powder, or translucent crystal chunks as the hydrochloride salt. · Soluble in ethanol, DMF, and DMSO.

Store dry and tightly sealed in a light-resistant container at cool room temperature.

Cross-Tolerance & Dependence Profile

mood elevation develops rapid within-session tolerance after 2–3 redoses; cross-tolerant with all dopaminergic stimulants (Hexen, cocaine, pyrovalerones, amphetamines), halving in 3–7 days and resetting in 1–2 weeks. Moderately to highly addictive with strong automatic repeated exposure risk.

Codes on this card

Short meanings for the abbreviations printed with this substance.

Open the full glossary →
DAT Dopamine transporter

DAT is the protein that collects dopamine back from the gap between nerve cells. A card that names DAT is quoting a laboratory result about that protein.

NET Norepinephrine transporter

NET is the protein that collects norepinephrine, also called noradrenaline, back into the nerve cell. Cards cite it when a lab report shows activity at that transporter.

SERT Serotonin transporter

SERT is the protein that collects serotonin back into the nerve cell. A higher number than at DAT means the serotonin transporter needed more concentration to reach the halfway point.

SNDRA / NDRI Releaser or reuptake blocker

An SNDRA is carried in and the cell releases serotonin, norepinephrine, and dopamine. An NDRI mainly slows the vacuum at norepinephrine and dopamine. The class line says which one the papers describe.

EC₅₀ / IC₅₀ Halfway concentration

EC50 is the concentration where a lab saw half of the maximum measured effect. IC50 is the concentration where it saw half of the maximum block. Smaller means that halfway point came at a lower concentration.

ratio Selectivity ratio

A selectivity ratio divides two halfway numbers, such as SERT EC50 by DAT EC50, to show which target the assay reached first. The direction of the division has to be stated, or the number flips.

5-HT ↑↑ Serotonergic Overload (Serotonin Toxicity)

A potentially fatal medical emergency caused by excessive synaptic serotonin (for example when mixing two serotonin releasers, MAOIs, or tramadol), marked by hyperthermia and neuromuscular rigidity.

HR / Naczynia Vasoconstriction & Cardiovascular Load

Narrowing of peripheral blood vessels, elevated blood pressure, and rapid heart rate driven by strong noradrenergic and dopaminergic stimulation.

Comprehensive Analytical & Toxicological Monograph

NEP (N-ethylpentedrone / N-ethylnorpentedrone; 2-(ethylamino)-1-phenylpentan-1-one; freebase CAS 779974-89-9, hydrochloride CAS 18268-16-1, PubChem CID 205593 [related CID 205592]) is an N-ethylated valerophenone cathinone supplied as pure analytical crystalline powder or crystals (C13H19NO, 205.30 g/mol). Unlike ring-substituted methcathinones (3-MMC, 4-MMC) that evoke neurotransmitter release, NEP acts in human HEK293 transporter assays as a pure norepinephrine-dopamine reuptake inhibitor (hNET IC50 = 101 nM, hDAT IC50 = 165 nM), exhibiting ~64-fold weaker activity at the serotonin transporter (hSERT IC50 = 10,500 nM). Human observational data confirm marked elevations in sociability, openness, and alertness alongside a mean +22.3 bpm heart-rate and +20.6 mmHg systolic blood-pressure increase across 4 hours. Because NEP is 3–4 times more potent per milligram than MMC/CMC cathinones, accurate milligram weighing is mandatory: oral threshold effects start at 10 mg, light stimulation spans 10–25 mg (mucosal 10–20 mg), common sociable stimulation occurs at 25–40 mg (mucosal 20–40 mg), strong intensity appears at 40–60 mg, and heavy overdose/psychosis risk begins above 60 mg. Oral effects last 4–6 hours, whereas mucosal intake peaks in 30–60 minutes over a 1–3 hour primary window. Positive mood declines quickly after 2–3 doses while residual wakefulness and tachycardia stack for up to 12–24 hours, making repeated exposure binges unproductive and hazardous. Compared to Hexen (N-ethylhexedrone), NEP feels smoother, warmer, and less peripherally jittery, while remaining far more manageable than ultra-potent pyrovalerones (alpha-PVP, alpha-PiHP). Never combine NEP with MAOIs, cocaine, Hexen, pyrovalerones, MDMA, tramadol, or 25x-NBOMe.

Chemical Architecture & Structural Profile

NEP (2-(ethylamino)-1-phenylpentan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C13H19NO and a molar mass of 205.3 g/mol. The parent molecule is indexed under CAS registry number 779974-89-9 and in the NCBI PubChem database as CID 205593 (Standard InChIKey: QQAHEGDXEXIQPR-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), NEP is indexed within the Cathinone structural group. Toxicological notes (PsychonautWiki): exact toxic threshold is unknown. Dependence liability (PsychonautWiki): moderately addictive with a high potential for abuse. Documented cross-tolerance class: dopamine, stimulant. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations

Documented Contraindications & Interactions

High-risk / Dangerous combinations

Unsafe combinations (elevated hazard)

Uncertain combinations (caution advised)